GLP1R and diabetes mellitus: Comparison of the GLP‐1 group with controls demonstrated a 12% risk reduction in cardiovascular‐related death (n = 87 434, RR 0.88, 95% CI 0.82−0.94, p = 0.0011) and both subgroups of type 2 diabetics (n = 64 852, RR 0.88, 95% CI 0.81−0.97), and overweight/obese patients without diabetes (n = 22 582, RR 0.85, 95% CI 0.73−0.98) had statistically significantly reduced risk of cardiovascular mortality (Figure 3D).